ストックスクリーナーアプリを入手
10.59
1.24%
0.13
アフターアワーズ：
10.51
-0.08
-0.76%
前日終値:
$10.46
開ける：
$10.51
24時間の取引高:
185.66K
Relative Volume:
0.46
時価総額：
$603.25M
収益：
-
当期純損益:
$-66.86M
株価収益率:
-8.825
EPS:
-1.2
ネットキャッシュフロー:
$-58.82M
1週間 パフォーマンス:
+12.06%
1か月 パフォーマンス:
+9.97%
6か月 パフォーマンス:
+163.43%
1年 パフォーマンス:
+109.29%
1日の値動き範囲:
$10.41
$10.97
1週間の範囲:
$9.36
$10.97
52週間の値動き範囲:
$2.60
$10.97
Design Therapeutics Inc Stock (DSGN) Company Profile
名前
Design Therapeutics Inc
セクター
電話
858-293-4900
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.59 | 595.84M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 開始されました | Oppenheimer | Outperform |
| 2025-12-03 | 開始されました | Craig Hallum | Buy |
| 2025-12-03 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-05-04 | アップグレード | Goldman | Sell → Neutral |
| 2022-06-10 | 開始されました | Wedbush | Outperform |
| 2022-05-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-19 | 開始されました | Goldman | Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-20 | 開始されました | Piper Sandler | Overweight |
| 2021-04-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Design Therapeutics Inc (DSGN) 最新ニュース
Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
Design Therapeutics (NASDAQ:DSGN) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics - Business Wire
Trading Recap: Will Bullfrog AI Holdings Inc Equity Warrant stock recover after earningsQuarterly Profit Report & Real-Time Volume Spike Alerts - baoquankhu1.vn
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighHere's What Happened - MarketBeat
Spinocerebellar Ataxias Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma - Barchart.com
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad - The AI Journal
Fuchs Dystrophy Clinical Trial Outlook: 5+ Companies and 7 Emerging Therapies Reshape the Global Treatment Pipeline, Says DelveInsight - Barchart.com
Fuchs Dystrophy Clinical Trial Outlook: 5+ Companies and 7 - openPR.com
Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline - openPR.com
Is Design Therapeutics Inc. stock heavily shortedEarnings Summary Report & Weekly Chart Analysis and Trade Guides - bollywoodhelpline.com
Can Design Therapeutics Inc. stock beat market expectations this quarterStop Loss & Verified High Yield Trade Plans - bollywoodhelpline.com
Design Therapeutics (NASDAQ:DSGN) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Shares Down 6.5%Time to Sell? - MarketBeat
Design Therapeutics (DSGN) Price Target Increased by 10.64% to 13.26 - Nasdaq
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design - Business Wire
Relmada Therapeutics Provides Regulatory Update Confirming - GlobeNewswire
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why - MSN
Press Release Service: Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases - CRISPR Medicine News
Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases - BioSpace
Can Protara Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Design Therapeutics (NASDAQ:DSGN) Shares Down 10%What's Next? - MarketBeat
Los Angeles Daily NewsDesign Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - FinancialContent
Resistance Break Could Fuel Sailani Tours N Travels Limited RallyEnergy Sector Updates & High Profit Investment Ideas - bollywoodhelpline.com
Oppenheimer Initiates Coverage of Design Therapeutics (DSGN) with Outperform Recommendation - Nasdaq
Design Therapeutics, Inc.Common Stock (NQ: DSGN - FinancialContent
Oppenheimer Initiates Design Therapeutics at Outperform With $18 Price Target - MarketScreener
Quarterly Recap: Is Design Therapeutics Inc stock a contrarian buyJuly 2025 Setups & Community Verified Trade Signals - Bộ Nội Vụ
Design Therapeutics (NASDAQ:DSGN) Shares Gap UpHere's What Happened - MarketBeat
What analysts say about Design Therapeutics Inc stockMarket Sentiment Shifts & Breakthrough Stock Performance - Early Times
2026 world cup analysis predictions: How sustainable is Design Therapeutics Inc. stock dividend payout2026 world cup usa national team round of 16 defensive leaders build up play tactical prediction statistical analysis - Улправда
Why Design Therapeutics Inc. stock appeals to analysts2026 world cup usa national team semifinals goalkeepers counter attacking winner prediction preview - Улправда
Wall Street Zen Upgrades Design Therapeutics (NASDAQ:DSGN) to "Hold" - MarketBeat
Design Therapeutics Inc Stock Analysis and ForecastTrading Psychology Tips & Free Discover Breakout Stocks Early - Early Times
Design Therapeutics (NASDAQ:DSGN) Trading Down 4.5% – Here’s Why - Defense World
Design Therapeutics Inc (NASDAQ:DSGN) Nasdaq Index Genetic Focus - Kalkine Media
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5%What's Next? - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Design Therapeutics, Inc. (NASDAQ:DSGN) Nasdaq Futures Neurology Programs - Kalkine Media
Risk Analysis: Is Design Therapeutics Inc stock dividend yield sustainableEarnings Recap Summary & Real-Time Price Movement Reports - moha.gov.vn
How sustainable is Design Therapeutics Inc. stock dividend payoutWatch List & Pattern Based Trade Signal System - Улправда
Investment Report: Will Ingredion Incorporated stock benefit from green energy trendsJuly 2025 Closing Moves & Detailed Earnings Play Strategies - moha.gov.vn
Design Therapeutics Shares Gain Momentum on Clinical Progress - AD HOC NEWS
➡️ Break above $200 with volume bullish continuationBreakout Stock Watch & Free Stock Trading Signal Access - Bollywood Helpline
Weekly Earnings: Is Design Therapeutics Inc. stock a good choice for value investorsJuly 2025 Retail & Community Consensus Stock Picks - Улправда
Why Design Therapeutics Inc. stock is rated strong buy2025 Price Action Summary & Technical Pattern Based Signals - Улправда
Design Therapeutics (NASDAQ:DSGN) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Is Design Therapeutics Inc. stock a good choice for value investorsSwing Trade & Risk Managed Investment Signals - Улправда
Design Therapeutics Inc (DSGN) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):